跳至主要内容
临床试验/KCT0002448
KCT0002448已完成未知

Outcomes of intravitreal aflibercept (Eylea®) treatment for treatment-naïve contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye

Seoul National University Hospital0 个研究点目标入组 21 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
21

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
40(Year) 至 o Limit(—)
性别
All

入选标准

  • Patients who developed new-onset nAMD in a second-affected eye, who had previously shown a poor response to as-needed ranibizumab in their first-affected eyes. Patients were diagnosed with nAMD when there was evidence of choroidal neovascularization (CNV) associated with nondrusenoid retinal pigment epithelium detachment (PED), serous or hemorrhagic retinal detachment, subretinal hemorrhage, subretinal pigment epithelial hemorrhage, or subretinal fibrosis.

排除标准

  • (1) patients with diabetic retinopathy or retinal vein occlusion, (2) patients with coexisting epiretinal membranes or vitreomacular traction syndrome, (3) patients with neovascularized maculopathies other than AMD, such as pathological myopia, angioid streaks, and (4) patients with a history of prior photocoagulation, intravitreal anti-VEGF injection, photodynamic therapy, intravitreal or sub-tenon steroid injection, vitrectomy surgery, or intravitreal gas injection.

研究者

相似试验

Outcomes of intravitreal aflibercept (Eylea®)... | 临床试验